BR112022019758A2 - Agente imunoteranóstico alvejando células cancerígenas derivadas de células-tronco mesenquimais e doença associada a células-tronco mesenquimais - Google Patents
Agente imunoteranóstico alvejando células cancerígenas derivadas de células-tronco mesenquimais e doença associada a células-tronco mesenquimaisInfo
- Publication number
- BR112022019758A2 BR112022019758A2 BR112022019758A BR112022019758A BR112022019758A2 BR 112022019758 A2 BR112022019758 A2 BR 112022019758A2 BR 112022019758 A BR112022019758 A BR 112022019758A BR 112022019758 A BR112022019758 A BR 112022019758A BR 112022019758 A2 BR112022019758 A2 BR 112022019758A2
- Authority
- BR
- Brazil
- Prior art keywords
- mesenchymal stem
- stem cells
- lrrc15
- immunotheranostic
- cells
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 title abstract 4
- 230000008685 targeting Effects 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 abstract 5
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 abstract 5
- 238000003745 diagnosis Methods 0.000 abstract 1
- 230000036210 malignancy Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063003598P | 2020-04-01 | 2020-04-01 | |
| PCT/US2021/025054 WO2021202642A2 (en) | 2020-04-01 | 2021-03-31 | Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019758A2 true BR112022019758A2 (pt) | 2023-01-31 |
Family
ID=77929889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019758A BR112022019758A2 (pt) | 2020-04-01 | 2021-03-31 | Agente imunoteranóstico alvejando células cancerígenas derivadas de células-tronco mesenquimais e doença associada a células-tronco mesenquimais |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230133775A1 (https=) |
| EP (1) | EP4125991A4 (https=) |
| JP (1) | JP2023520392A (https=) |
| KR (1) | KR20220161395A (https=) |
| CN (1) | CN115379848A (https=) |
| AU (1) | AU2021246485A1 (https=) |
| BR (1) | BR112022019758A2 (https=) |
| CA (1) | CA3174263A1 (https=) |
| WO (1) | WO2021202642A2 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
| WO2024081729A2 (en) * | 2022-10-12 | 2024-04-18 | Mythic Therapeutics, Inc. | Lrrc-15-binding protein constructs and uses thereof |
| TW202434310A (zh) * | 2023-01-27 | 2024-09-01 | 日商第一三共股份有限公司 | 抗lrrc15抗體 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025160129A1 (en) * | 2024-01-23 | 2025-07-31 | The Regents Of The University Of California | Methods of use of agents targeting mesenchymal stem cell- derived tumors and tumor associated cells |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025264059A1 (ko) * | 2024-06-20 | 2025-12-26 | 주식회사 에디스바이오텍 | Lrrc15에 특이적으로 결합하는 항체 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862770B2 (en) * | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| AR090549A1 (es) * | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
| SG10201900002QA (en) * | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| JP2016056165A (ja) * | 2014-08-12 | 2016-04-21 | 学校法人藤田学園 | 抗α６β４インテグリン抗体を利用したがん又は腫瘍の診断又は治療のための抗体製剤及び抗体キット |
| AU2016365114A1 (en) * | 2015-11-30 | 2018-05-17 | Abbvie Biotherapeutics Inc. | Anti-huLRRC15 antibody drug conjugates and methods for their use |
| EP3383910A1 (en) * | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
| US10221242B2 (en) * | 2016-01-21 | 2019-03-05 | Pfizer Inc. | Antibodies specific for epidermal growth factor receptor variant III and their uses |
| WO2018083087A2 (en) * | 2016-11-02 | 2018-05-11 | Glaxosmithkline Intellectual Property (No.2) Limited | Binding proteins |
| EP3634485A4 (en) * | 2017-06-07 | 2021-07-21 | Silverback Therapeutics, Inc. | CONJUGATES OF ANTIBODIES CONTAINING IMMUNOMODULATOR COMPOUNDS AND THEIR USES |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| US20210154188A1 (en) * | 2018-04-02 | 2021-05-27 | Silverback Therapeutics, Inc. | Alk5 inhibitors, conjugates, and uses thereof |
| CN112041337B (zh) * | 2018-04-16 | 2025-01-07 | 日本医事物理股份有限公司 | 修饰抗体、及放射性金属标记抗体 |
-
2021
- 2021-03-31 CA CA3174263A patent/CA3174263A1/en active Pending
- 2021-03-31 BR BR112022019758A patent/BR112022019758A2/pt unknown
- 2021-03-31 JP JP2022559435A patent/JP2023520392A/ja active Pending
- 2021-03-31 AU AU2021246485A patent/AU2021246485A1/en active Pending
- 2021-03-31 EP EP21780744.5A patent/EP4125991A4/en active Pending
- 2021-03-31 WO PCT/US2021/025054 patent/WO2021202642A2/en not_active Ceased
- 2021-03-31 KR KR1020227037264A patent/KR20220161395A/ko active Pending
- 2021-03-31 US US17/915,377 patent/US20230133775A1/en active Pending
- 2021-03-31 CN CN202180025582.7A patent/CN115379848A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4125991A2 (en) | 2023-02-08 |
| WO2021202642A2 (en) | 2021-10-07 |
| KR20220161395A (ko) | 2022-12-06 |
| CA3174263A1 (en) | 2021-10-07 |
| JP2023520392A (ja) | 2023-05-17 |
| US20230133775A1 (en) | 2023-05-04 |
| WO2021202642A3 (en) | 2021-11-11 |
| AU2021246485A1 (en) | 2022-11-17 |
| EP4125991A4 (en) | 2025-02-26 |
| CN115379848A (zh) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019758A2 (pt) | Agente imunoteranóstico alvejando células cancerígenas derivadas de células-tronco mesenquimais e doença associada a células-tronco mesenquimais | |
| PH12019500604A1 (en) | Anti-muc16 (mucin 16) antibodies | |
| CR20200566A (es) | Anticuerpos anti-sirpa y metodos de utilización de los mismos | |
| ZA202100721B (en) | Anti-mesothelin antibodies | |
| MY199468A (en) | Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof | |
| MX2019012869A (es) | Anticuerpos anti-sortilina y metodos para su uso. | |
| Tokunaga et al. | Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
| BR112016002000A2 (pt) | Diagnóstico e terapia de câncer envolvendo células-tronco tumorais | |
| BR112021008549A2 (pt) | Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor | |
| BR112021009275A2 (pt) | Anticorpo humanizado anti-sirp alfa ou um fragmento de ligação a antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, e, célula hospedeira. | |
| BR112022020232A2 (pt) | Anticorpos contra nkp46 e construtos dos mesmos para o tratamento de cânceres e infecções | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| BR112022001733A2 (pt) | Anticorpos anti-ms4a4a e métodos de uso dos mesmos | |
| MX2025003476A (es) | Anticuerpos anti-il-27 y usos de los mismos | |
| EP4219556A3 (en) | Human monoclonal antibodies specific for flt3 and uses thereof | |
| BR112023022774A2 (pt) | Terapias de combinação para tratamento de câncer | |
| BR112022005678A2 (pt) | Métodos e composições para o tratamento da retinopatia diabética | |
| BR112021025077A2 (pt) | Anticorpos anti-sortilina para uso em terapia | |
| MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
| BR112021024826A2 (pt) | Anticorpo anti-cd25 e aplicação do mesmo | |
| WO2018064013A8 (en) | METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR | |
| EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
| Gennigens et al. | Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy |